A Prospective Randomized Study on the Preventive Effect of Japanese Herbal Kampo Medicine Goreisan for Recurrence of Chronic Subdural Hematoma

Naoaki Fujisawa,1 Soichi Oya,1 Shinsuke Yoshida,1 Tsukasa Suchiya,1 Takumi Nakamura,1 Masahiro Indo,1 and Toru Matsui1

1Department of Neurosurgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan

Abstract

Although the recurrence of chronic subdural hematoma (CSDH) after surgical treatment significantly affects the patients’ quality of life, the recurrence rate has not improved in decades. Goreisan, a Japanese herbal Kampo medicine, promotes the hydragogue effect and has been empirically used in the treatment of CSDH in Japan. We conducted a prospective randomized study to investigate whether Goreisan treatment decreases the recurrence rate of CSDH. Between March 2013 and December 2018, a total of 224 patients who underwent initial burr hole surgery for CSDH were randomly assigned to receive Goreisan for 3 months (Group G) or no medication (Group N). The primary endpoint was symptomatic recurrence within 3 months postoperatively, and the secondary endpoint was complications, including the adverse effects of Goreisan. Of 224 randomized patients, 208 were included in the final analysis (104 in Group G and 104 in Group N). The overall recurrence rate was 9.1% (19/208). The recurrence rate of Group G was lower than that of Group N (5.8% vs 12.5%, \( P = 0.09 \)), but the difference was not statistically significant. However, a significant preventive effect of Goreisan was found in 145 patients with high-risk computed tomography (CT) features, namely, homogeneous and separated types (5.6% vs 17.6%, \( P = 0.04 \)). Although the present study did not prove the beneficial effect of Goreisan treatment, it suggested the importance of selecting patients with an increased risk of recurrence. A subset of patients whose hematoma showed homogeneous and separated patterns on CT image might benefit from Goreisan treatment.

Keywords: chronic subdural hematoma, Goreisan, prospective randomized trial, recurrence

Introduction

Chronic subdural hematoma (CSDH) can develop in all generations from infants to elderly individuals. It is common especially among the aged population and has been gradually recognized as “not benign” but serious clinical condition reflecting general frailty in elderly individuals.1,2 In Japan, CSDH develops in 13.1–20.6 per 100000 person in the general population.3,4 However, these numbers increase to 58.1–80.1 in individuals aged >65 years.3,4 Although a relatively simple surgical treatment usually consisting of burr hole opening and drainage of the hematoma is effective, recurrence occurs postoperatively at 5.4–18.1%.5–16 In symptomatic reaccumulation of hematoma, repetitive drainage or craniotomy is often required, but redo surgery may have a negative impact on the neurological status and patients’ quality of life. Several retrospective analyses have reported the benefit of adjuvant medical treatment, such as corticosteroid,17,18 atorvastatin,19,20 tranexamic acid,21 etizolam,22 and angiotensin-converting enzyme (ACE) inhibitor,23 to lower the recurrence rate. Although some prospective trials for the abovementioned medications have been conducted, the effectiveness of these medical treatments has not been proven in the context of a prospective randomized study.24-27

Regarding the mechanism of CSDH development, Gardner emphasized the role of the osmotic ingress of the cerebrospinal fluid into the cavity formed by
Effect of Goreisan to Prevent CSDH Recurrence

Neurol Med Chir (Tokyo) 61, January, 2021

the inner membrane of hematoma. In fact, an early study demonstrated the therapeutic effect of an osmotic diuretic agent, mannitol, as nonsurgical treatment of CSDH. Goreisan, a Japanese herbal Kampo medicine, is a mixture of five herbs including Alisma Rhizome, Atractylodes Lancea Rhizome, Polyporus Sclerotium, Poria Sclerotium, and Cinnamon bark. It is also known as Oreongsan in Korea. Since it promotes the hydragogue effect, in Japan, Goreisan has been empirically administered in patients with CSDH. Although several small case series mostly from Japan showed the clinical effect of Goreisan to replace or enhance the effect of surgical treatment, the reliable data collected in a prospective and randomized fashion are scarce. Recently, Katayama et al. conducted a prospective randomized trial for patients aged >60 years and evaluated whether Goreisan treatment lowers the recurrence rate. Although no beneficial effect for overall participants was observed, their subanalysis revealed that the recurrence rate was successfully lowered by Goreisan treatment in patients aged 60–74 years, indicating its potential benefit to relatively younger patients. This prospective randomized study on patients with CSDH, including young adults, aimed to investigate whether Goreisan treatment effectively reduces the recurrence rate of CSDH and which cluster of patients will benefit from this treatment.

Materials and Methods

Study design

This study was approved by the institutional review board (No. 705-III). Patients who underwent initial surgery for symptomatic CSDH confirmed on computed tomography (CT) images were recruited in this study. The primary endpoint was the symptomatic recurrence of CSDH, and the secondary endpoint was the complications, including the adverse side effects of Goreisan. The sample size was determined as follows. We previously reported that the recurrence rate of CSDH at our institution was 8.9%. Therefore, we postulated an estimated recurrence rate of 10% in the control group and 2% in the group receiving Goreisan. The estimated sample size for the two-tailed t-test was determined to be 224 when Type I and Type II errors were considered at 0.05 and 0.20, respectively. Enrollment was conducted between March 1, 2013, and December 31, 2018. Written informed consent was obtained from all enrolled patients. Patients aged ≤ 18 years, those with a history of surgery for CSDH and hematological disorders, and those who had been using Goreisan before surgery were excluded. Additionally, patients with other intracranial lesions, such as brain tumors or arachnoid cysts, were also excluded because these conditions have been reportedly associated with risk of CSDH. The study protocol was registered at a clinical trial registry with number UMIN000010006. Data collected include age, sex, history of recent head injury, history of infarction, alcohol consumption, hypertension, diabetes, and hemodialysis. Moreover, current use of medications, such as antiplatelets, anticoagulants, and ACE inhibitors, statins, and steroids, was analyzed. Heavy drinking was defined as alcohol intake of ≥ 60 g/day. We also conducted radiological classification based of CT images into four subtypes according to the Nakaguchi classification. Homogeneous type was defined as hematoma exhibiting homogenous density regardless of low or high. Laminar type was defined as hematoma consisting of two or more layers with different densities. Hematomas were defined as separated type when they had a border of density (upper low, lower high). Trabecular type was defined as heterogeneous hematoma containing trabeculae running between the inner and outer membranes of hematoma.

Patient enrollment

We recruited participants in this study from March 2013 to November 2018. During this period, a total of 381 patients with CSDH underwent initial surgical treatment from March 2013 to November 2018 at our institution. By initial survey, four patients aged < 18 years, two patients who had craniotomy based on hematoma characteristics, and one patient under treatment for myelodysplastic syndrome were excluded. Another patient was not enrolled because she had large arachnoid cyst on the same side of CSDH. After the detailed explanation of the study protocol, 149 patients refused to participate in this study. Consequently, the study registration was terminated when 224 patients agreed to participate and were randomly assigned by drawing lots to the group receiving Goreisan (Group G) or the group receiving no medication (Group N).

Burr hole surgery

Our surgical indication and protocol are shown elsewhere. Briefly, a single burr hole was opened on the skull over the CSDH, and the hematoma was irrigated with saline solution under local anesthesia. Then, a closed drainage system using a silicone tube was placed in the hematoma cavity for 12–24 h postoperatively except patients for whom tube placement was considered dangerous. Postoperatively, CT was performed immediately after surgery and day 1 to exclude adverse events, such as postoperative
bleeding before discharge. In patients with bilateral CSDH, only the symptomatic side was treated. When both sides were regarded as symptomatic, surgery was conducted for both sides. Irrigation was conducted on both side when both sides were considered symptomatic. Patients on antiplatelet therapy underwent immediate surgery without discontinuing the antiplatelet treatment, whereas those using anticoagulants underwent elective surgery after the anticoagulative effect was reversed with vitamin K2 or fresh frozen plasma until normalization of prothrombin time or international normalized ratio was confirmed.

Goreisan administration and follow-up strategy
Postoperatively, patients assigned to the Group G started to receive oral Tsumura Goreisan extract granules (Tsumura & Co., Tokyo, Japan), 7.5 g, three times a day within a few days. Patients were instructed to continue Goreisan for at least 3 months unless they developed any side effect of Goreisan. Three months postoperatively, continuation of Goreisan was allowed as per surgeons’ judgment when a significant amount of hematoma remained on CT. Most patients were discharged home within a week and visits our outpatient clinic regularly for checkup. Recurrence was defined as reaccumulation of symptomatic CSDH. In some patients who were sent to rehabilitation centers before returning home and unable to visit our outpatient clinic, whether the patient had symptomatic recurrence was assessed on the phone at 3–6 months postoperatively.

Statistical analysis
Pearson’s chi-square test and Fisher’s exact test (if any of the cells in $2 \times 2$ table is $<5$) were used to compare categorical variables. Continuous variables with non-normal distributions were presented as median (interquartile range) and compared using the Wilcoxon–Mann–Whitney test. Multiple logistic regression analysis for calculation of odds ratios (ORs) to determine the characteristics associated with increased recurrence risk. $P$ values $<0.05$ were considered statistically significant. All analyses were performed with JMP 14 (SAS Institute, Cary, NC, USA).

Results
A flow diagram for patient enrollment and randomization is presented in Fig. 1. Between March 2013 and November 2018, a total of 224 patients were
enrolled in this study. From Group G, seven patients were excluded because of lost to follow-up (n = 5), discontinuation of Goreisan due to side effect (n = 1), and postoperative cerebral embolism occurring on postoperative day 1 requiring decompressive craniectomy (n = 1). Additionally, protocol violation was confirmed after enrollment: one patient reported history of idiopathic thrombocytopenic purpura immediately after enrollment. In Group N, seven patients were also excluded due to lost to follow-up. Moreover, a protocol violation was reported after enrollment (n = 1): one patient had been receiving Goreisan preoperatively at a referring hospital. Consequently, both Group G and Group N comprised 104 patients.

Patient demographics and CT classifications of CSDH are shown in Table 1. All characteristics except for the use of anticoagulant (P = 0.004) were matched between two groups. Table 2 demonstrates the primary and secondary outcomes. The overall recurrence rate was 9.1% (19/208). The recurrence rate of Group G was lower than that of Group N, but it was not statistically significant (5.8% vs 12.5%; OR, 0.42; 95% confidence interval [CI], 0.15–1.17; P = 0.09). Although it was not significant, there was a tendency that patients aged <70 years receiving Goreisan treatment less frequently had recurrence than those not receiving Goreisan treatment (3.0% vs 16.7%; OR, 0.15; 95% CI, 0.02–1.34; P = 0.11). No therapeutic effect of Goreisan treatment was observed among patients aged >70 years (7.0% vs 10.3%; OR, 0.66; 95% CI, 0.20–2.19; P = 0.50). The occurrence of wound infection was not significant between the two groups (P = 0.57). No seizure was observed in Group G. Among three patients complaining of severe headache, diarrhea, and abdominal
discomfort, one patient with headache was not able to tolerate and discontinued Goreisan treatment. The possible influence of other factors was investigated (Table 3). Univariate analysis revealed that heavy drinking was associated with increased risk of recurrence (21.1% vs 4.2%, \( P = 0.003 \)). After multivariate analysis adjusting for Goreisan use, heavy drinking was an independent risk factor for increased recurrence rate (OR: 5.47, 95% CI: 1.31–20.0, \( P = 0.02 \)). We also found that the recurrence rates were different according to CT classification (Fig. 2A). Although no significant difference was found between any groups (\( P = 0.27 \)), the risk of recurrence after surgery for laminar or trabecular type of CSDH was sufficiently low considering the overall recurrence rate (Fig. 2B). Therefore, we confined the analysis for these high-risk hematomas, namely, homogeneous and separated types, and found that the recurrence rate was significantly lower in patients receiving Goreisan treatment than those not receiving Goreisan treatment (5.6% vs 17.6%, \( P = 0.04 \), Fig. 2C).

**Discussion**

Although burr hole opening and drainage of hematoma is a well-established and safe treatment for CSDH, the recurrence rate of CSDH has not decreased in recent decades, indicating the necessity to improve current treatment strategy. In addition to surgical treatment, several studies have investigated the benefit of additional medical treatments, including corticosteroid, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor to minimize the risk of recurrence. Although these retrospective studies demonstrated some positive effects to lower the recurrence rates, the result of previous prospective randomized trials implies the limited effect of these adjuvant therapies to prevent the recurrence of CSDH. The present study did not show the beneficial effect of Goreisan to lower the recurrence rate. However, it suggested that Goreisan treatment might be effective for CSDH manifesting homogeneous and separated types on CT.

**Therapeutic mechanism of Goreisan treatment**

Although the mechanism of the therapeutic effect of Goreisan remains to be elucidated, an immunohistochemical study demonstrated that the outer membrane of CSDH expressed aquaporin-4 (AQP4). AQP4 is the major water transporter protein in the central nervous system and increases water permeability of cell membranes. A recent experimental study suggested that the possible mechanism of the hydragogue effect of Goreisan is via its suppressive effect on the expression and function of AQP4.

**Treatment outcome of Goreisan administration**

In Japan, Goreisan has been empirically administered to patients with CSDH in expectation of its hydragogue effect. In addition to small case series reporting its therapeutic effect, a recent retrospective large observational study using a national inpatient database in Japan demonstrated that the reoperation rate of patients with CSDH who started receiving Goreisan treatment within 2 days postoperatively was lower than that of those who did not receive Goreisan treatment. This robust statistical analysis of 36020 patients, including 3889 patients treated with Goreisan, showed that Goreisan treatment was associated with a reduction of reoperation rate from 6.2 to 4.8%. Such findings prompted us to start the prospective randomized trial to verify the effect of adjuvant Goreisan treatment. Three randomized trials

| Outcomes                          | Group G n = 104 | Group N n = 104 | OR (95% CI)       | \( P \) value |
|-----------------------------------|-----------------|-----------------|-------------------|--------------|
| **Primary outcome**               |                 |                 |                   |              |
| Recurrence, n (%)                 |                 |                 |                   |              |
| All                               | 6(5.8)          | 13(12.5)        | 0.42 (0.15–1.17)  | 0.09         |
| Age <70 (n = 69)                   | 1(3.0)          | 6(16.7)         | 0.15 (0.02–1.34)  | 0.11         |
| Age ≥70 (n = 139)                  | 5(7.0)          | 7(10.3)         | 0.66 (0.20–2.19)  | 0.50         |
| **Secondary outcome**             |                 |                 |                   |              |
| Wound infection, n (%)            | 1(1.0)          | 2 (1.9)         | 0.50 (0.04–5.60)  | 0.57         |
| Seizure, n (%)                    | 0               | 1 (1.0)         | NC                | NC           |
| Adverse effects of Goreisan, n (%)| 3 (2.9)         | –               | NC                | NC           |

NC: not calculable, OR: odds ratio.

*Neurol Med Chir (Tokyo) 61, January, 2021*
controlled studies including the present study have been conducted on the effect of Goreisan to prevent recurrence, but none of those could prove the benefit of Goreisan treatment.\(^\text{27,37}\) Although some previous studies have discussed the surgical strategy might affect the recurrence rate,\(^\text{12,48}\) it would have little impact on those negative results because the recurrence rates of control patients in two previous studies were 9.8% and 12.5%; it was quite comparable to the result of our study (Group N, 12.5%). The number of participants of the three prospective trials including the present study ranged from 180 to 224 and failed to show significant decrease in the recurrence rate due to Goreisan treatment. These facts appear to indicate that we might have overestimated the favorable effect of Goreisan.

**Patient selection to prevent CSDH recurrence by Goreisan treatment**

There is still a possibility that a certain cluster of patients might benefit from Goreisan treatment. For example, a study by Katayama et al. found that Goreisan had a favorable effect in patients aged 60–74 years while no beneficial effect was observed in patients aged ≥75 years.\(^\text{37}\) Our data also showed a similar tendency in patients aged <70 years. We conducted additional analysis to seek the relevance of CT findings because some previous studies demonstrated the association between the radiological features on CT image and recurrence rate of CSDH.\(^\text{10,41}\) Our data demonstrated that Goreisan might effectively lower the recurrence rate specifically for patients with high-risk characteristics on CT image. The importance of risk stratification based on CT images in Goreisan treatment was also confirmed on a recent retrospective analysis.\(^\text{49}\) Another randomized controlled study regarding adjuvant dexamethasone treatment with surgery for CSDH recently disclosed the result of the interim analysis.\(^\text{25}\) In their study, recurrence occurred significantly less frequently with dexamethasone administered for 2 weeks postoperatively (0% vs 21%). Although the result is promising, dexamethasone may cause various adverse effects, such as infection and would dehiscence; it should also be avoided in patients with diabetes. In contrast, Goreisan is an herbal medicine with few side effects. Based on the analysis of the secondary outcome of the present study, it appears as another advantage of this supportive therapy.

| Factor                                      | Univariate analysis |          | Multivariate analysis |          |
|---------------------------------------------|---------------------|----------|-----------------------|----------|
|                                             | Recurrence n = 19   | No recurrence n = 189 | \(P\) value | OR       | 95% CI     | \(P\) value |
| Age, median (IQR), years                   | 74 (66, 79)         | 74 (67, 82) | 0.69                  |          |            |            |
| Sex, male, n (%)                           | 14 (73.7)           | 139 (73.5) | 0.98                  |          |            |            |
| Current antiplatelet therapy, n (%)        | 3 (15.8)            | 21 (11.1)  | 0.54                  |          |            |            |
| Current anticoagulant therapy, n (%)       | 0 (0)               | 8 (4.2)    | 0.36                  |          |            |            |
| Current ACE inhibitor therapy, n (%)       | 2 (10.5)            | 4 (2.1)    | 0.10                  |          |            |            |
| Current statin therapy, n (%)              | 3 (15.8)            | 18 (9.5)   | 0.42                  |          |            |            |
| Current steroid therapy, n (%)             | 0 (0)               | 2 (1.1)    | 1.00                  |          |            |            |
| History of cerebral infarction, n (%)      | 2 (10.5)            | 13 (6.9)   | 0.56                  |          |            |            |
| History of hypertension                    | 10 (52.6)           | 88 (46.6)  | 0.61                  |          |            |            |
| History of diabetes mellitus               | 3 (15.8)            | 33 (17.5)  | 0.85                  |          |            |            |
| History of recent head injury, n (%)       | 11 (57.9)           | 119 (63.0) | 0.66                  |          |            |            |
| Heavy drinking                             | 4 (21.1)            | 8 (4.2)    | 0.003                 | 5.47     | 1.31–20.0 | 0.02       |
| Hemodialysis                               | 0 (0)               | 2 (1.1)    | 1.00                  |          |            |            |
| Goreisan treatment, n (%)                  | 6 (31.6)            | 98 (51.9)  | 0.09                  | 0.46     | 0.16–1.26 | 0.13       |

ACE: angiotensin-converting enzyme, CI: confidence interval, IQR: interquartile range, OR: odds ratio.
Group G in this study as a result of randomization. Although views are split regarding whether the use of anticoagulant increases the risk of recurrence, the consequence is that none of these patients had recurrence in this study; however, it remains unknown whether this excellent outcome in patients on anticoagulant is attributable to Goreisan treatment.

**Study limitations**
There are some limitations in our study. First, we might have overestimated the favorable effect due to the lack of preliminary data and available studies, which might lead to recruitment of an insufficient number of patients and the negative result for primary outcome. Second, this study was conducted at a single center; therefore, it should be validated in the form of multi-institutional approach.

**Conclusions**
The present prospective randomized study did not prove the beneficial effect of adjuvant Goreisan treatment, although it approached significance to lower the recurrence rate in overall patients. However, it suggested the importance of selecting patients with high risk of recurrence. Based on our data, a...
subset of patients whose hematoma showed homogeneous and separated patterns on CT image might benefit from Goreisan treatment.

**Conflict of Interest Disclosure**

The authors have no conflict of interest to declare.

**References**

1) Miranda LB, Braxton E, Hobbs J, Quigley MR: Chronic subdural hematoma in the elderly: not a benign disease. *J Neurosurg* 114: 72–76, 2011
2) Uno M, Toi H, Hirai S: Chronic subdural hematoma in elderly patients: is this disease benign? *Neurol Med Chir (Tokyo)* 57: 402–409, 2017
3) Karibe H, Kameyama M, Kawase M, Hirano T, Kawaguchi T, Tominaga T: Epidemiology of chronic subdural hematomas. *No Shinkei Geka* 39: 1149–1153, 2011 (Japanese)
4) Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N: Chronic subdural hematoma in elderly people: present status on Awaji Island and epidemiological prospect. *Neurol Med Chir (Tokyo)* 32: 207–209, 1992
5) Andersen-Ranberg NC, Debrabant P, Poulsen FR, Bergholt B, Hundsholt T, Fugleholm K: The Danish chronic subdural hematoma study-predicting recurrence of chronic subdural hematoma. *Acta Neurochir (Wien)* 161: 885–894, 2019
6) Han MH, Ryu JL, Kim CH, Kim JM, Cheong JH, Yi HJ: Predictive factors for recurrence and clinical outcomes in patients with chronic subdural hematoma. *J Neurosurg* 127: 1117–1125, 2017
7) Kim J, Moon J, Kim T, et al.: Risk factor analysis for the recurrence of chronic subdural hematoma: a review of 368 consecutive surgical cases. *Korean J Neurotrauma* 11: 63–69, 2015
8) Motiei-Langroudi R, Stippler M, Shi S, et al.: Factors predicting reoperation of chronic subdural hematoma following primary surgical evacuation. *J Neurosurg* 129: 1143–1150, 2018
9) Mutoi R, Karashima S, Otsuji R, et al.: Recurrence in 787 patients with chronic subdural hematoma: retrospective cohort investigation of associated factors including direct oral anticoagulant use. *World Neurosurg* 118: e87–e91, 2018
10) Ridwan S, Bohrer AM, Grote A, Simon M: Surgical treatment of chronic subdural hematoma: predicting recurrence and cure. *World Neurosurg* 128: e1010–e1023, 2019
11) Santarius T, Qureshi HU, Sivakumaran R, Kirkpatrick PJ, Kirollos RW, Hutchinson PJ: The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. *World Neurosurg* 73: 747–750, 2010
12) Santarius T, Kirkpatrick PJ, Ganesan D, et al.: Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. *The Lancet* 374: 1067–1073, 2009
13) Santos RGD, Xander PAW, Rodrigues LHDS, Costa GHFD, Veiga JCE, Aguilar GB: Analysis of predisposing factors for chronic subdural hematoma recurrence. *Rev Assoc Med Bras* (1992) 65: 834–838, 2019
14) Stavrinou P, Katsigiannis S, Lee JH, et al.: Risk factors for chronic subdural hematoma recurrence identified using quantitative computed tomography analysis of hematoma volume and density. *World Neurosurg* 99: 465–470, 2017
15) Torihashi K, Sadamasa N, Yoshida K, Narumi O, Chinn M, Yamagata S: Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. *Neurosurgery* 63: 1125–1129; discussion 1129, 2008
16) You W, Zhu Y, Wang Y, et al.: Prevalence of and risk factors for recurrence of chronic subdural hematoma. *Acta Neurochir (Wien)* 160: 893–899, 2018
17) Berghauser Pont LME, Dammers R, Schouten JW, Lingsma HF, Dirven CMF: Clinical factors associated with outcome in chronic subdural hematoma: a retrospective cohort study of patients on preoperative corticosteroid therapy. *Neurosurgery* 70: 873–880; discussion 880, 2012
18) Holl DC, Volovici V, Dirven CMF, et al.: Corticosteroid treatment compared with surgery in chronic subdural hematoma: a systematic review and meta-analysis. *Acta Neurochir (Wien)* 161: 1231–1242, 2019
19) Tang R, Shi J, Li X, et al.: Effects of atorvastatin on surgical treatments of chronic subdural hematoma. *World Neurosurg* 117: e425–e429, 2018
20) Xu M, Chen P, Zhu X, Wang C, Shi X, Yu B: Effects of atorvastatin on conservative and surgical treatments of chronic subdural hematoma in patients. *World Neurosurg* 91: 23–28, 2016
21) Kageyama H, Toyooka T, Tsuzuki N, Oka K: Non-surgical treatment of chronic subdural hematoma with tranexamic acid. *J Neurosurg* 119: 332–337, 2013
22) Hirashima Y, Kurimoto M, Nagai S, Hori E, Origasa H, Endo S: Effect of platelet-activating factor receptor antagonist, etizolam, on resolution of chronic subdural hematoma – a prospective study to investigate use as conservative therapy. *Neurol Med Chir (Tokyo)* 45: 621–626; discussion 626, 2005
23) Weigel R, Schmiedek P, Krauss JK: Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. *J Neurol Neurosurg Psychiatr* 74: 937–943, 2003
24) Bartek J, Sjävik K, Schaible S, et al.: The role of angiotensin-converting enzyme inhibitors in patients with chronic subdural hematoma: a scandinavian population-based multicenter study. *World Neurosurg* 113: e555–e560, 2018
25) Mebberson K, Colditz M, Marshman LAG, Thomas PAW, Mitchell PS, Robertson K: Prospective randomized placebo-controlled double-blind clinical study of adjuvant dexamethasone with surgery for chronic subdural haematoma with post-operative subdural drainage: interim analysis. *J Clin Neurosci* 71: 153–157, 2020
26) Poulsen FR, Munthe S, Søe M, Halle B: Perindopril and residual chronic subdural hematoma volumes six weeks after burr hole surgery: a randomized trial. Clin Neurol Neurosurg 123: 4–8, 2014

27) Yamada T, Natori Y: Prospective study on the efficacy of orally administered tranexamic acid and goreisan for the prevention of recurrence after chronic subdural hematoma burr hole surgery. World Neurosurg 134: e549–e553, 2020

28) Gardner JW: Traumatic subdural hematoma with particular reference to the latent interval. Arch Neurol Psychiatry 1932: 847–858, 1932

29) Suzuki J, Takaku A: Nonsurgical treatment of chronic subdural hematoma. J Neurosurg 33: 548–553, 1970

30) Miyagami M, Kagawa Y: Effectiveness of Kampo medicine Gorei-San for chronic subdural hematoma. No Shinkei Geka 37: 765–770, 2009 (Japanese)

31) Kwon S, Jin C, Cho KH: Oreongsan, an herbal medicine prescription developed as a new alternative treatment in patients with chronic subdural hematoma: a narrative review. Integr Med Res 8: 26–30, 2019

32) Cho KH, Kwon S, Jung WS, Moon SK: Herbal medicine, oreongsan for recurrent chronic subdural hematoma: a case report. Explore (NY) 13: 139–141, 2017

33) Goto S, Kato K, Yamamoto T, Shimato S, Ohshima T, Nishizawa T: Effectiveness of Goreisan in preventing recurrence of chronic subdural hematoma. Asian J Neurosurg 13: 370–374, 2018

34) Muramatsu M, Yoshikawa T, Hanabusa K: Effectiveness of kampo medicine gorei-san-ryo for chronic subdural hematoma in very elderly patients. No Shinkei Geka 33: 965–969, 2005 (Japanese)

35) Okamura A, Kawamoto Y, Sakoda E, Murakami T, Hara T: Evaluation of recurrence factors and Goreisan administration for chronic subdural hematoma percutaneous subdural tapping. Hiroshima J Med Sci 62: 77–82, 2013

36) Wakabayashi Y, Yamashita M, Asano T, et al.: Effect of Gorei-san with tranexamic acid for preventing recurrence of chronic subdural hematoma. No Shinkei Geka 40: 967–971, 2012 (Japanese)

37) Katayama K, Matsuda N, Kakuta K, et al.: The effect of Goreisan on the prevention of chronic subdural hematoma recurrence: multi-center randomized controlled study. J Neurotrauma 35: 1537–1542, 2018

38) Okano A, Oya S, Fujisawa N, et al.: Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: optimal management of patients on antiplatelet therapy. Br J Neurosurg 28: 204–208, 2014

39) McKenzie CR, Rengachary SS, McGregor DH, Dixon AY, Suskind DL: Subdural hematoma associated with metastatic neoplasms. Neurosurgery 27: 619–624; discussion 624–625, 1990

40) Mori K, Yamamoto T, Horinaka N, Maeda M: Arachnoid cyst is a risk factor for chronic subdural hematoma in juveniles: twelve cases of chronic subdural hematoma associated with arachnoid cyst. J Neurotrauma 19: 1017–1027, 2002

41) Nakaguchi H, Tanishima T, Yoshimasu N: Factors in the natural history of chronic subdural hematomas that influence their postoperative recurrence. J Neurosurg 95: 256–262, 2001

42) Neidert MC, Schmidt T, Mitova T, et al.: Preoperative angiotensin converting enzyme inhibitor usage in patients with chronic subdural hematoma: associations with initial presentation and clinical outcome. J Clin Neurosci 28: 82–86, 2016

43) Qiu S, Zhuo W, Sun C, Su Z, Yan A, Shen L: Effects of atorvastatin on chronic subdural hematoma: a systematic review. Medicine (Baltimore) 96: e7290, 2017

44) Basaldella L, Perin A, Orvieto E, et al.: A preliminary study of aquaporin 1 immunolocalization in chronic subdural hematoma membranes. J Clin Neurosci 17: 905–907, 2010

45) Papadopoulos MC, Verkman AS: Aquaporin water channels in the nervous system. Nat Rev Neurosci 14: 265–277, 2013

46) Yano Y, Yano H, Takahashi H, et al.: Goreisan inhibits upregulation of Aquaporin 4 and formation of cerebral edema in the rat model of juvenile hypoxic-ischemic encephalopathy. Evid Based Complement Alternat Med 2017: 3209219, 2017

47) Yasunaga H: Effect of Japanese herbal Kampo medicine Goreisan on reoperation rates after burr-hole surgery for chronic subdural hematoma: analysis of a national inpatient database. Evid Based Complement Alternat Med 2015: 817616, 2015

48) Soleman J, Lutz K, Schaedelin S, et al.: Subperisosteal vs subdural drain after burr-hole drainage of chronic subdural hematoma: a randomized clinical trial (cSDH-Drain-Trial). Neurosurgery 85: E825–E834, 2019

49) Harada Y, Yoshida K, Nojiri S, Kurihara Y, Kobayashi H, Arai H: Identification of chronic subdural hematoma types most responsive to Goreisan, Kampo medicine: a retrospective study. J Clin Neurosci 78: 198–202, 2020

50) Miki K, Abe H, Morishita T, et al.: Double-crescent sign as a predictor of chronic subdural hematoma recurrence following burr-hole surgery. J Neurosurg 131: 1905–1911, 2019

Corresponding author: Soichi Oya, MD, PhD
Department of Neurosurgery, Saitama Medical Center, 1981 Kamoda, Kawagoe, Saitama 350-8550, Japan.
e-mail: sooya-tky@umin.ac.jp

Neurol Med Chir (Tokyo) 61, January, 2021